RVL Pharmaceuticals Focuses on Scaling Upneeq as Market Momentum Builds
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
RVL Pharmaceuticals reported 22% revenue growth for Upneeq in Q3 2025 and announced leadership changes to support continued expansion of the product.
The agency is seeking public comment on a proposal to classify bemotrizinol as generally recognized as safe and effective for over-the-counter sunscreens.